Healthy Clinical Trial
Official title:
Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test
Objectives:
To establish valid serum total cortisol and salivary cut-offs for use with the short
Synacthen test in patients with normal CBG concentrations.
To investigate, using current assays, the effect of assay differences on the serum total
cortisol cut-off.
To explore the performance of these cut-offs in groups of patients with suspected adrenal
insufficiency and high and low serum CBG concentration.
Methodology: An ACTH test (250 micrograms iv ACTH1-24) will be undertaken in healthy
volunteers, women taking an oestrogen-containing oral contraceptive pill (OCP), patients with
adrenal insufficiency and patients with low serum albumin. Serum cortisol in the samples
collected from healthy volunteers will be measured using GC-MS, Advia Centaur (Siemens),
Architect (Abbott), Modular Analytics E170 (Roche), Immulite 2000 (Siemens) and Access
(Beckman) automated immunoassays. The estimated lower reference limit for the 30 min cortisol
response to ACTH, defined as the 2.5th percentile of log-transformed concentrations, will be
determined in this healthy population and used as a cut-off in the patient groups studied.
Synacthen® is a synthetic analogue of ACTH which has been used since the 1960s to assess
adrenal sufficiency. It is now well established as a first line test to investigate diseases
of the hypothalamo-pituitary-adrenal axis and to assess adrenal function in patients on
long-term corticosteroid therapy. Briefly, cortisol is measured before and after injection of
250 micrograms of Synacthen®. In a normal individual serum cortisol will rise to
concentrations greater than an arbitrary value (typically 550 nmol/l) 30 minutes after
administration of Synacthen®.
In 2004 the All Wales Clinical Biochemistry Audit group surveyed protocols for performing and
interpreting short Synacthen® tests. This identified wide differences in practice within
Wales. As a result standards were drawn up for performance of the test. It was noted that
there was considerable variability or bias between cortisol immunoassays and that the
cortisol cut-off chosen for interpretation of the short Synacthen® test should be method
dependent.
Clark et al., in 1998 reported cortisol cut-offs following Synacthen® using 4 well
established commercially available cortisol immunoassays. This study demonstrated
considerable differences between the cortisol immunoassays used in clinical laboratories at
the time. It was also apparent that there were differences in gender-related responses to
Synacthen® although there was no dependence on age. In the 8 years since publication of this
study there have been advances in formulation of cortisol immunoassays as well as the
instrumentation used to perform analyses. At the University Hospital of Wales cortisol is
currently assayed using the Bayer Centaur automated immunoassay analyser. This assay was not
available at the time of the study by Clark et al.,. The investigators' current short
Synacthen® test cut-offs therefore rely on historical reference ranges which have become
outdated. A re-evaluation of the cortisol cut-off is required to ensure that patients are not
incorrectly classified.
It has been long been recognised that oestrogens (including ethinyloestradiol prescribed in
combined oral contraceptive pills) increase total (but not free) serum cortisol levels. The
degree of increase is related to the dose used and is thought to be due to an elevation in
cortisol binding globulin (CBG). However, no comparisons of total serum cortisol in response
to Synacthen® have been performed between women taking oestrogens and those who are not.
Knowledge of the salivary cortisol response may also be useful in patients with decreased
serum CBG concentrations e.g. severe nephrotic syndrome in whom the serum cortisol response
may be misleading. The investigators therefore plan to measure salivary cortisol as part of
the investigators' study protocol to assess the response of free cortisol.
17 Hydroxyprogesterone (17OHP) is an intermediate in the biosynthesis of cortisol. Deficiency
of 21-hydroxylase enzyme activity leads to an increased concentration of 17OHP in the
peripheral circulation. The short Synacthen® test can be used to assist in diagnosis of mild
cases of congenital adrenal hyperplasia. Current reference ranges are taken from the
literature.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |